Latest insight from Medicines Law & Policy

Protecting Public Health through Technology Transfer: The Unfulfilled Promise of the TRIPS Agreement

Ellen 't Hoen -
This article was previously published by the Health and Human Rights Journal. The scrambling for access to COVID-19 vaccines by developing countries has reignited the...

How not to solve a crisis: The European Commission’s Plan for Transferable Data Exclusivity...

Ellen 't Hoen -
Drug-resistant infections, sometimes called “superbugs,” killed an estimated 1.27 million people in 2019, a number set to rise to 50 million by 2050. It is...

Right to breathe takes precedence over company profits: Families of cystic fibrosis patients seek...

Kaitlin Mara -
“Not even the doctors believed it would be so miraculous,” says 22-year old Rafaella Pereira. In two days, a new cystic fibrosis medicine took...

ML&P’s Comments to the Intergovernmental Negotiating Body (INB) on the Zero Draft of the...

Ellen 't Hoen -
These remarks were delivered on the occasion of the fourth meeting of the Intergovernmental Negotiating Body to draft and negotiate a WHO convention, agreement...

Pharmaceutical Accountability Foundation is taking AbbVie to court over excessive pricing of Humira –...

Ellen 't Hoen -
On 22 February, the Dutch Pharmaceutical Accountability Foundation (PAF) took the bold step to take AbbVie to court, claiming the company’s pricing policy had harmed the Dutch healthcare system and the people who make use of it.

Medicines price transparency: Ground still left to cover

Katrina Perehudoff -
Parts of this blog were previously published in the Lancet Regional Health Europe Secret medicines prices are hotly debated as European health systems struggle to...

Subscribe to Our Newsletter

Never miss a post! Sign up for ML&P's mailing list by entering your information below. The list will only be used to inform you of new content (messages are sent approximately once a month).

Posts by Subject

Abbvie Access to Medicines Access to Vaccines ARIPO AstraZeneca C-TAP Cancer CDCA competition law Compulsory licensing compulsory licensing for export covid-19 Covid-19 Pool Covid-19 vaccine Data exclusivity Delinkage DNDi European Commission European Union evergreening Fair Pricing Gilead Hepatitis C human rights IFPMA LDCs market exclusivity Medicines Patent Pool Medicines Pricing Netherlands Orphan Drugs pandemic treaty Patents R&D remdesivir Sofosbuvir technology transfer The Netherlands transparency TRIPS Council TRIPS flexibilities TRIPS Waiver vaccines WHO WTO
 This work is licensed under Creative Commons.